Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza|
|Citation:||Clinical and Experimental Pharmacology and Physiology, 2004; 31(7):429-432|
|Publisher:||Blackwell Publishing Asia|
|Latte, Jenny ; Taverner, David ; Slobodian, Peter ; Shakib, Sepehr|
|Abstract:||1. The aim of the present study was to assess the efficacy of pseudoephedrine in coryza. 2. In a double-blind, randomized, placebo-controlled design, 48 adults with acute coryza received a single oral dose of 60 mg pseudoephedrine (Sudafed; Pfizer Consumer HealthCare Group, Caringbah, NSW, Australia) or matching placebo. Before and after dosing, nasal airway resistance (NAR), nasal volume, the minimum intranasal cross-sectional area (MCA) and the symptom of nasal congestion were measured. 3. Pseudoephedrine produced a significant decrease in NAR (P = 0.005; 95% confidence interval (CI) 0.073, 0.383). Nasal volume increased, but this did not reach significance (P = 0.07; 95% CI -0.842, 0.034). There was no change in MCA and symptoms. 4. In conclusion, pseudoephedrine has a moderate effect in decreasing objective measures of nasal congestion in coryza.|
|Keywords:||Humans; Nasal Obstruction; Ephedrine; Nasal Decongestants; Rhinometry, Acoustic; Double-Blind Method; Reproducibility of Results; Time Factors; Adolescent; Adult; Middle Aged; Female; Male|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.